From: Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States
Germany
United States
GDP per capita in $ in 2018
54,457
62,853
Factor
Cost-effectiveness thresholds in $/LY (QALY)
3
163,371
188,559
6
326,742
377,118
9
490,113
565,677